2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Non-Hodgkin Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

5367 Population pharmacokinetics and exposure–response analyses to support an alternate mogamulizumab dosing regimen (2 mg/kg Q4W) in cutaneous T-cell lymphoma

Ragini Vuppugalla, Carlos Sepulveda2, Dimple Patel3, Pooya Aavani4, Matthew W Hruska5, Douglas Marsteller6
1 Kyowa Kirin, Inc., Princeton, New Jersey, United States
2 Kyowa Kirin, Inc., Princeton, New Jersey, United States
3 Kyowa Kirin, Inc., Princeton, New Jersey, United States
4 Kyowa Kirin, Inc., Princeton, New Jersey, United States
5 Kyowa Kirin, Inc., Princeton, New Jersey, United States
6 Kyowa Kirin, Inc., Princeton, New Jersey, United States

Introduction

Mogamulizumab, an anti-CCR4 monoclonal antibody, is approved for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) after ≥1 prior systemic therapy. The approved dosing regimen, after weekly 1 mg/kg intravenous (IV) infusions during the first 4-week loading cycle, is 1 mg/kg IV infusion every 2 weeks (Q2W) during each subsequent 4-week cycle (1 mg/kg Q2W). An alternate dosing regimen of 2 mg/kg every 4 weeks (2 mg/kg Q4W) was explored after the first 4-week loading cycle, to reduce the number of required clinic visits. This analysis evaluated population pharmacokinetics (PPK) and exposure–response (ER) relationships for efficacy and safety to support the 2 mg/kg Q4W regimen.

Methods

The integrated PPK analysis included 816 participants (median age, 63 years [range, 19–101 years]; 57.0% male) from 12 mogamulizumab monotherapy or combination studies spanning doses of 0.01–3 mg/kg and QW, Q2W, Q3W, and Q4W regimens. ER analyses of efficacy (overall response rate [ORR], progression-free survival [PFS]) and safety included 216 participants (MF, 60.6%; SS, 39.4%) from 2 studies and 473 participants from 8 studies, respectively.

PPK model development evaluated structural, interindividual-variability, residual-error, and covariate components. Average, maximum, and minimum mogamulizumab concentrations (Cavg, Cmax, and Cmin) at Cycle 2 and steady state were predicted and compared for mogamulizumab 2 mg/kg Q4W and 1 mg/kg Q2W. ER relationships between ORR or PFS and mogamulizumab exposure using Cmin at Cycle 2, and time to first event for 4 groups of treatment-emergent adverse events of special interest (TEAESI) and mogamulizumab exposure using Cmax at Cycle 2 were evaluated for 2 mg/kg Q4W and 1 mg/kg Q2W. The TEAESI groups were Grade 3/4 adverse events (AEs), infections, skin/subcutaneous rash events, and immune-mediated events. Supportive pharmacodynamic assessments observed in 2 mogamulizumab studies of 2 mg/kg Q4W and 1 mg/kg Q2W evaluated changes in circulating malignant T cells.

Results

Mogamulizumab pharmacokinetics was adequately described using a 2-compartment model with linear clearance, interindividual variability on clearance and central volume, and a combined proportional and additive residual-error model. The model accounted for clinically relevant effects of body weight, albumin, sex, race, and hepatic function. Steady state was achieved by approximately Cycle 4 for 2 mg/kg Q4W and 1 mg/kg Q2W.

 

Compared with 1 mg/kg Q2W, predicted exposure for 2 mg/kg Q4W at Cycle 2 and steady state, respectively, resulted in a 46.4% and 46.7% higher Cmax and a 23.5% and 34.7% lower Cmin. Also, compared with 1 mg/kg Q2W, predicted Cavg for 2 mg/kg Q4W was 16.1% higher at Cycle 2 and was essentially unchanged at steady state (0.2% higher).

A linear logistic regression model identified a positive exposure–ORR relationship, with cutaneous T-cell lymphoma subtype retained in the final model. Model-predicted ORR for 1 mg/kg Q2W vs 2 mg/kg Q4W was 21.3% (95% uncertainty interval [UI], 15.5%–28.4%) vs 18.3% (95% UI, 13.2%–25.1%) in participants with MF and 41.1% (95% UI, 31.6%–50.8%) vs 36.3% (95% UI, 27.7%–45.8%) in participants with SS. The 95% UIs overlapped between regimens within each subtype. No exposure–PFS relationship was identified; predicted 12-month PFS was comparable for 1 mg/kg Q2W vs 2 mg/kg Q4W in participants with MF (33.9% vs 32.1%) and SS (49.4% vs 47.9%).

Cox proportional hazards models described time to each TEAESI. Applying the fitted models to regimen-specific simulated exposures yielded comparable model-predicted 6-month probabilities for 1 mg/kg Q2W vs 2 mg/kg Q4W: Grade 3/4 AEs (48.7% vs 48.4%), infections (36.2% vs 35.3%), skin/subcutaneous rash events (44.5% vs 47.2%), and immune-mediated events (25.5% vs 24.7%). Supportive pharmacodynamic assessments showed comparable reductions in circulating malignant T cells between the two dosing regimens.

Conclusions

PPK analyses suggest the alternate mogamulizumab dosing regimen (2 mg/kg Q4W) would result in mogamulizumab exposures that are efficacious and tolerable. The ER analyses demonstrated comparable ORR, PFS, and TEAESI for 2 mg/kg Q4W and 1 mg/kg Q2W (approved dosing). These results support use of the alternate mogamulizumab dosing regimen as a treatment for certain patients with relapsed/refractory MF or SS who may have logistical challenges in receiving Q2W dosing.

 

Funding

The work was funded by Kyowa Kirin, Inc.

Ragini Vuppugalla: Kyowa Kirin Inc - Current Employment